Rhodojaponin VI ameliorates podocyte injury related with MDM2 /Notch1 pathway in rat experimental membranous nephropathy
Nephrology · 2024
DOI: 10.1111/nep.14337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology, 2024. Verfasst von Anni Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Podocytes, Receptor, Notch1, Proto-Oncogene Proteins c-mdm2. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Hubei Province, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Aim
Rhodojaponin VI (R‐VI) is the key compound of Rhododendron molle G. Don (Ericaceae) (RM) with effective clinical application in rheumatoid arthritis and chronic glomerulonephritis. In our study, we tried to explore the effect of R‐VI on the rat model of membranous nephropathy.
Methods
The rat model of passive heymann nephritis (PHN) was established by injecting sheep anti‐rat Fx1A serum at a single dose through the tail. The rats were orally administered R‐VI (0.02 mg/kg) or FK506 (1 mg/kg) 1 day before PHN induction, which was kept for 4 weeks. Urine and blood samples as well as kidney tissue were collected for analysis. C5b‐9‐induced human podocyte cell (HPC) was employed for experiments in vitro.
Results
R‐VI could alleviate glomerulonephritis progression and podocyte injury in PHN rats, as indicated by the decreased proteinuria and the elevated level of albumin, accompanied with reduced immune deposits, reversed podocyte injury in the kidneys. Furthermore, R‐VI suppressed murine double minute 2 (MDM2) expression without the alteration in the protein level of p53 and decreased Notch1 expression independent of Numb regulation. Pre‐treatment with R‐VI in C5b‐9‐induced HPC blocked MDM2/Notch1 signalling pathway.
Conclusion
Thus, R‐VI ameliorates podocyte injury in rats with PHN, which was probably related with MDM2/Notch1 signalling pathway. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Chun Zhang
Förderung
- National Natural Science Foundation of China
- Key Research and Development Program of Hubei Province
- China Postdoctoral Science Foundation
Zitieren
APA
Song, A., Yan, R., Qiu, Y., Yin, X., Xiong, J., Yao, G., & Zhang, C. (2024). Rhodojaponin VI ameliorates podocyte injury related with MDM2 /Notch1 pathway in rat experimental membranous nephropathy. Nephrology. https://doi.org/10.1111/nep.14337
Vancouver
Song A, Yan R, Qiu Y, Yin X, Xiong J, Yao G, et al. Rhodojaponin VI ameliorates podocyte injury related with MDM2 /Notch1 pathway in rat experimental membranous nephropathy. Nephrology. 2024. doi:10.1111/nep.14337
BibTeX
@article{Song2024,
author = {Song, Anni and Yan, Ruiwei and Qiu, Yue and Yin, Xingjie and Xiong, Jing and Yao, Guangmin and Zhang, Chun},
title = {Rhodojaponin VI ameliorates podocyte injury related with MDM2 /Notch1 pathway in rat experimental membranous nephropathy},
journal = {Nephrology},
year = {2024},
doi = {10.1111/nep.14337}
}
EUVIMED